SecBot SecBot
10-K/A ·Filed Apr 24, 2026

ACLX

Arcellx, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed6mo ago SEC0001193125-26-177460
Amended annual report (potential restatement)
Actionable Insight • Neutral

This is a routine procedural filing with no material impact. Traders should note that all Part III information is now available and no further proxy statement incorporation is needed. Monitor the upcoming proxy statement for any potential changes to compensation or governance that were not included in this amendment.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK AT ENTRY AT T+5
Entry
$115.07
T+0 close · Apr 24, 2026 · via day close
Latest settled
0.00%
T+5 · $115.07
Vs SPY
−0.40%
α at T+5
Next horizon
T+20
due 6mo ago
  1. T+0 · Apr 27 $115.07entry
  2. T+1 · 7mo ago 0.00%α +0.49% · $115.07
  3. T+5 · 7mo ago 0.00%α −0.40% · $115.07
  4. T+20 · due 6mo ago Pending
  5. T+60 · due 4mo ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Arcellx filed an amended 10-K/A to include Part III disclosures (director and executive compensation, ownership, and related-party transactions) that were omitted from its original 10-K and would have otherwise been incorporated by reference from a future proxy statement. The amendment also includes required CEO and CFO certifications. No financial data or other disclosures were revised. This is a routine procedural filing.

Key Facts

  • The 10-K/A is an amendment to include Part III disclosures (Items 10-14) that were omitted from the original 10-K filing.
  • The original filing relied on General Instruction G(3) to incorporate Part III by reference from a future proxy statement, but the company chose to file the information directly via this amendment.
  • No financial statements, results, or other disclosures from the original 10-K were changed or updated.
  • The filing includes required Rule 13a-14(a) certifications from the CEO and CFO.
  • The amendment is purely procedural and does not reflect any changes in the company's financial condition, operations, or governance.

Financial Impact

No financial impact. This is a disclosure-only amendment.

Risk Factors

  • None related to this filing. The amendment itself carries no risk.
  • General biotech risks include clinical trial outcomes for anito-cel and integration risks related to the pending acquisition by Gilead.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
0% bullish (23 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
10-K/A Filing (Primary)0001193125-26-177460
Document: d332400dex311.htm0001193125-26-177460
Document: d332400dex312.htm0001193125-26-177460
Document: 0001193125-26-177460-index-headers.html0001193125-26-177460
Document: 0001193125-26-177460-index.html0001193125-26-177460
Document: 0001193125-26-177460.txt0001193125-26-177460

Track record

3 reports on ACLX

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Apr 28, 202628w ago 25-NSE Bearish 9/10 Entry $115.07 to $115.07 · 0.00% −0.01% vs SPY
  2. Apr 24, 202629w ago 10-K/A Neutral 2/10 Viewing Entry $115.07 to $115.07 · 0.00% +0.49% vs SPY
  3. Feb 25, 202637w ago Insider Cluster Bearish 7/10 Entry $113.76 to $113.88 ▼ −0.11% −0.65% vs SPY
Showing 3 of 3

US Market Status

Market Closed · Opens Wed (11h 5m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 24, 2026